A pilot open label randomized controlled study to evaluate the dose tolerance safety and efficacy of VT-122 regimen for the treatment of cachexia in subjects with stage IV non-small cell lung cancer

Trial Profile

A pilot open label randomized controlled study to evaluate the dose tolerance safety and efficacy of VT-122 regimen for the treatment of cachexia in subjects with stage IV non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2013

At a glance

  • Drugs Propranolol/etodolac (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2009 Actual end date (September 2008) added as reported by ClinicalTrials.gov.
    • 06 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2008 The final study report is expected in June 2008, according to a media release from Vicus Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top